XIFYRM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XIFYRM (XIFYRM).
XIFYRM is a monoclonal antibody that targets and neutralizes interleukin-36 (IL-36), thereby inhibiting the inflammatory signaling cascade involved in pustular psoriasis.
| Metabolism | XIFYRM is a monoclonal antibody; metabolism is expected to involve degradation into small peptides and amino acids via general protein catabolism. |
| Excretion | Renal: 70% unchanged; Fecal: 20%; Biliary: <10% |
| Half-life | Terminal elimination half-life: 15 hours; prolonged in renal impairment (creatinine clearance <30 mL/min) to 30 hours |
| Protein binding | 93% bound to serum albumin; also binds to alpha-1-acid glycoprotein |
| Volume of Distribution | 1.2 L/kg; indicates extensive tissue distribution, exceeding total body water |
| Bioavailability | Oral: 85% (range 80-90%); Subcutaneous: 100%; Intravenous: 100% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes |
| Duration of Action | Oral: 12-24 hours; Intravenous: 6-12 hours; due to sustained-release formulation for oral route |
| Molecular Weight | 340.42 |
500 mg orally twice daily with food.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-89 mL/min: 500 mg twice daily. GFR 15-29 mL/min: 500 mg once daily. GFR <15 mL/min or dialysis: 500 mg every 48 hours. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 250 mg twice daily. Child-Pugh C: Not recommended. |
| Pediatric use | For patients >12 years and >=40 kg: 500 mg twice daily. For patients 6-12 years (20-39 kg): 250 mg twice daily. For patients <6 years: Not established. |
| Geriatric use | No specific dose adjustment based on age alone; monitor renal function and adjust per renal criteria. |
| 1st trimester | Limited data. Crosses placenta. Avoid in first trimester due to potential teratogenicity (animal studies show skeletal and visceral malformations). |
| 2nd trimester | Human pregnancy data lacking. Use only if potential benefit outweighs risk. Monitor for oligohydramnios. |
| 3rd trimester | May cause neonatal withdrawal syndrome (irritability, feeding difficulties). Avoid in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for XIFYRM (XIFYRM).
| Placental transfer | Crosses placenta (human data: cord blood levels ~30% of maternal serum) |
| Breastfeeding | Excreted in breast milk in low concentrations. No adverse effects reported in infants. Monitor for diarrhea or rash. Consider benefits vs risks. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to XIFYRM or any excipientsConcurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine)Severe hepatic impairment (Child-Pugh class C)QTc interval prolongation (baseline QTc > 450 ms or history of torsades de pointes)
| Precautions | Increased risk of infections due to immunomodulation, Hypersensitivity reactions including anaphylaxis, Potential for reactivation of tuberculosis or other latent infections, Avoid live vaccines during treatment |
| Food/Dietary | No significant food interactions. Avoid alcohol as it may increase bleeding risk. |
| Clinical Pearls |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | XIFYRM is contraindicated in pregnancy. First trimester: High risk of major congenital malformations including craniofacial defects, neural tube defects, and cardiac anomalies. Second and third trimesters: Risk of spontaneous abortion, intrauterine growth restriction, and oligohydramnios. Embryo-fetal toxicity is dose-dependent. |
| Fetal Monitoring | Monitor pregnancy status prior to initiation and monthly during therapy. If pregnancy occurs, discontinue immediately. Perform ultrasound to assess fetal anatomy and amniotic fluid volume. Monitor maternal renal function, liver function, and electrolytes monthly. |
| Fertility Effects | XIFYRM impairs fertility in females by disrupting ovarian function and causing anovulation. In males, it reduces spermatogenesis and sperm motility. Fertility impairment is reversible upon discontinuation but may persist for several months. |
| XIFYRM (fibrinogen concentrate) is used for acute bleeding in congenital fibrinogen deficiency. Administer at 50-100 mg/kg IV, titrating to fibrinogen level >150 mg/dL. Monitor for thromboembolic events. Do not mix with other IV fluids. |
| Patient Advice | This medication is derived from human plasma and may carry risk of infectious agents despite screening. · Report any signs of allergic reaction (rash, itching, swelling) or thrombosis (chest pain, leg swelling, shortness of breath). · Avoid aspirin or NSAIDs unless prescribed, as they increase bleeding risk. · Maintain good oral hygiene and use soft toothbrush to prevent gum bleeding. |